a Laboratoire de Microbiologie clinique , Groupe Hospitalier Paris Saint-Joseph , Paris , France.
b Equipe mobile de Microbiologie clinique , Groupe Hospitalier Paris Saint-Joseph , Paris , France.
Infect Dis (Lond). 2018 Sep;50(9):668-677. doi: 10.1080/23744235.2018.1458147. Epub 2018 Apr 2.
Bloodstream infections (BSI) can potentially be life-threatening infections and are associated with a high crude mortality, moreover with an inappropriate first-line antibiotic therapy. Bacterial resistance is more and more frequently observed. New strategies of BSI management are urgently needed.
During an 18-months period, we prospectively evaluated the clinical impact of rapid bacterial identification by MALDI-TOF MS technology combined with an antimicrobial stewardship team (AST) intervention. Furthermore, during an 8-months period, we combined this strategy with the rapid detection of third-generation cephalosporin (3GC) resistance by the Bêta-LACTA™ test (BLT) directly on blood cultures. We then evaluated the theoretical impact of BLT on antibiotic therapy adaptation and establishment of infection control measures.
A total of 335 blood cultures were enrolled during the study. MALDI-TOF MS gave accurate identification for 301 blood cultures (89,8%) and led to early antibiotic therapy adaptation for 73 episodes (21.8%). BLT was performed on 141 blood cultures, revealing 28 3GC-resistant bacteria (19.9%). Twenty-one patients (75%) received a non-adapted first-line treatment. The antibiotic therapy adaptation was delayed by 28.1 hours and the establishment of infection control measures by 35 hours with antimicrobial susceptibility testing, compared to the theoretical adaptation with BLT result.
These tools can be included in a strategy of bloodstream infections management for a better patient care, optimizing and saving the use of antibiotics, notably carbapenems as well as diminishing the spread of multi-drug resistant bacteria by applying rapidly infection control measures.
血流感染(BSI)可能是危及生命的感染,与高粗死亡率相关,此外还与不适当的一线抗生素治疗有关。细菌耐药性越来越频繁地被观察到。迫切需要新的 BSI 管理策略。
在 18 个月的时间里,我们前瞻性地评估了 MALDI-TOF MS 技术快速细菌鉴定与抗菌药物管理团队(AST)干预相结合的临床效果。此外,在 8 个月的时间里,我们将这种策略与通过 Bêta-LACTA™测试(BLT)直接在血培养物上检测第三代头孢菌素(3GC)耐药性相结合。然后,我们评估了 BLT 对抗生素治疗适应和感染控制措施制定的理论影响。
研究期间共纳入 335 份血培养物。MALDI-TOF MS 对 301 份血培养物(89.8%)进行了准确鉴定,并使 73 例(21.8%)早期抗生素治疗适应。BLT 在 141 份血培养物上进行,发现 28 株 3GC 耐药菌(19.9%)。21 名患者(75%)接受了非适应性一线治疗。与 BLT 结果相比,抗生素治疗适应延迟了 28.1 小时,感染控制措施的建立延迟了 35 小时。
这些工具可以纳入血流感染管理策略,以更好地为患者提供护理,优化和节省抗生素的使用,特别是碳青霉烯类药物,并通过迅速实施感染控制措施减少多药耐药菌的传播。